InMode Ltd. (NASDAQ:INMD) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Analysts maintain a “Hold” consensus on InMode, with six hold, one sell and one buy rating among eight firms. The average 12-month price target is $16.00, compared with shares opening at $15.15.
• InMode’s latest quarterly results met expectations, reporting $0.35 in EPS and $95.59 million in revenue versus estimates of $94.89 million; however, EPS declined from $0.47 in the prior-year quarter.
• Institutional investors own 68.04% of the company’s stock, with several major funds increasing their positions during the first and second quarters.

InMode Ltd. (NASDAQ:INMD - Get Free Report) has been assigned a consensus recommendation of "Hold" from the eight research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $16.00.

Several equities research analysts have issued reports on the company. Barclays set a $19.00 price target on InMode and gave the stock an "overweight" rating in a report on Thursday, May 7th. Weiss Ratings reiterated a "sell (d+)" rating on shares of InMode in a research report on Thursday, August 6th. Finally, Robert W. Baird lowered their target price on InMode from $17.00 to $14.00 and set a "neutral" rating for the company in a research note on Thursday, May 7th.

InMode Stock Down 0.3%

Shares of INMD stock opened at $15.15 on Friday. InMode has a 12-month low of $12.72 and a 12-month high of $16.74. The firm has a market capitalization of $870.82 million, a price-to-earnings ratio of 12.32 and a beta of 1.89. The firm has a fifty day moving average of $14.68 and a 200-day moving average of $14.30.

InMode (NASDAQ:INMD - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The healthcare company reported $0.35 EPS for the quarter, hitting the consensus estimate of $0.35. The business had revenue of $95.59 million for the quarter, compared to the consensus estimate of $94.89 million. InMode had a return on equity of 11.99% and a net margin of 20.69%.The firm's revenue was up .0% compared to the same quarter last year. During the same quarter last year, the business posted $0.47 EPS.

Institutional Investors Weigh In On InMode

Large investors have recently made changes to their positions in the stock. Steadtrust LLC raised its holdings in shares of InMode by 251.9% during the second quarter. Steadtrust LLC now owns 91,500 shares of the healthcare company's stock worth $1,338,000 after acquiring an additional 65,500 shares during the period. Prospect Capital Advisors LLC boosted its stake in InMode by 50.6% in the 1st quarter. Prospect Capital Advisors LLC now owns 313,450 shares of the healthcare company's stock worth $4,288,000 after purchasing an additional 105,250 shares during the period. Janus Henderson Group PLC boosted its stake in InMode by 5.0% in the 1st quarter. Janus Henderson Group PLC now owns 932,132 shares of the healthcare company's stock worth $12,752,000 after purchasing an additional 44,575 shares during the period. Eversept Partners LP boosted its stake in InMode by 9.4% in the 1st quarter. Eversept Partners LP now owns 67,744 shares of the healthcare company's stock worth $927,000 after purchasing an additional 5,806 shares during the period. Finally, SummitTX Capital L.P. increased its holdings in InMode by 28.4% during the 1st quarter. SummitTX Capital L.P. now owns 42,914 shares of the healthcare company's stock worth $587,000 after purchasing an additional 9,498 shares in the last quarter. Institutional investors own 68.04% of the company's stock.

InMode Company Profile

InMode Ltd. NASDAQ: INMD is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode's product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source